Zentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Earnings Results, Misses Expectations By $0.10 EPS

Zentalis Pharmaceuticals (NASDAQ:ZNTL) issued its earnings results on Thursday. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.10), FiscalAI reports.

Zentalis Pharmaceuticals Trading Down 15.6%

Shares of NASDAQ ZNTL opened at $4.22 on Friday. The stock has a fifty day moving average price of $4.31 and a 200 day moving average price of $3.59. Zentalis Pharmaceuticals has a 12-month low of $1.21 and a 12-month high of $6.95. The company has a market cap of $300.42 million, a P/E ratio of -2.16 and a beta of 1.92.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ZNTL shares. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Mizuho began coverage on Zentalis Pharmaceuticals in a report on Friday, July 17th. They set an “outperform” rating and a $8.00 target price for the company. Wall Street Zen downgraded shares of Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, Guggenheim raised their price target on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a report on Friday, April 10th. Four analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $6.75.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ZNTL. AQR Capital Management LLC raised its holdings in shares of Zentalis Pharmaceuticals by 177.6% during the 1st quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock valued at $985,000 after buying an additional 396,233 shares during the period. Millennium Management LLC boosted its holdings in Zentalis Pharmaceuticals by 220.6% in the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after acquiring an additional 2,111,951 shares during the period. Qube Research & Technologies Ltd purchased a new position in Zentalis Pharmaceuticals in the 2nd quarter worth approximately $37,000. Sei Investments Co. grew its position in Zentalis Pharmaceuticals by 373.1% in the second quarter. Sei Investments Co. now owns 167,100 shares of the company’s stock valued at $194,000 after acquiring an additional 131,780 shares in the last quarter. Finally, Jane Street Group LLC raised its stake in shares of Zentalis Pharmaceuticals by 346.3% during the second quarter. Jane Street Group LLC now owns 664,061 shares of the company’s stock valued at $770,000 after purchasing an additional 515,257 shares during the period.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.